Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. [electronic resource]
Producer: 20201026Description: 7381-7387 p. digitalISSN:- 1557-3265
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms -- diagnostic imaging
- Breast Neoplasms, Male -- diagnostic imaging
- Female
- Fluorodeoxyglucose F18 -- metabolism
- Humans
- Male
- Middle Aged
- Outcome Assessment, Health Care
- Patient Selection
- Positron-Emission Tomography -- methods
- Protein Kinase Inhibitors -- therapeutic use
- Quinolines -- therapeutic use
- Radiopharmaceuticals -- metabolism
- Receptor, ErbB-2 -- genetics
- Response Evaluation Criteria in Solid Tumors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.